cautioned not to place undue reliance on any such
forward-looking statements, any of which may turn out to be wrong due to
inaccurate assumptions, unknown risks, uncertainties or other factors.
Genaera does not intend (and it is not obligated) to publicly update,
revise or correct these forward-looking statements or the risk factors that
may relate thereto.
GENAERA CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)
Three Months Ended Six Months Ended
June 30, June 30,
2008 2007 2008 2007
Revenues $ 45 $ 2,403 $ 1,354 $ 2,610
Costs and expenses:
Research and development 3,549 3,089 7,387 6,559
General and administrative 1,378 1,639 3,563 3,071
4,927 4,728 10,950 9,630
Loss from operations (4,882) (2,325) (9,596) (7,020)
Interest income 104 338 280 705
Loss before income taxes (4,778) (1,987) (9,316) (6,315)
Income tax benefit -- -- 281 147
Net loss $(4,778) $(1,987) $(9,035) $(6,168)
Net loss per share --
basic and diluted $(0.27) $(0.11) $(0.52) $(0.35)
Weighted average shares
outstanding -- basic and
diluted 17,465 17,449 17,464 17,446
CONDENSED BALANCE SHEETS
(Unaudited)
(In thousands)
June
'/>"/>
SOURCE Genaera Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Genaera Elects New Board Member and Announces Executive Appointments2.
Genaera to Present at Biotech 2007 and BIO InvestorForum3.
Genaera Corporation Announces Third Quarter Financial Results4.
Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference5.
Genaera Corporation Announces 2007 Financial Results6.
Genaera Corporation Announces First Quarter Financial Results7.
Genaera Corporation to Present at BIO Business Forum8.
Genaera Corporation Elects Paul K. Wotton to Board of Directors9.
Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue10.
PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation11.
AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II